Advanced searches left 3/3

Metastatic Lung Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

Prediction in Silico of Therapeutic Response in a Prospective Cohort Study of Metastatic Lung Cancer Patients

PDL1 – Squamous cell carcinoma with PDL1 50%: Carboplatin + bevacizumab + pedigolizumab alone, unless there is contraindication of pegblozumab. In the event of contralateral evidence of pembrolizumab, therapy will be based on a doublet of chemotherapy with platinum salt - Squamous cell carcinoma with PDL1 50%: Carboplatin + pemomycinab + pemozumab alone. For group 3: no small cell lung cancer with oncogenic drug therapy, TKI is not confirmed; doublet of chemotherapy with platinum salt +/- pemobolium is administered; in case of contraindication of pembrolizumab alone, TKI is not indicated. In the case of TKI, no small cell lung cancer with oncogenic drug is indicated; TKI is not indicated; If TKI is not indicated: chemotherapy with platinum salt +/-bevacizumab.

Source link: https://clinicaltrials.gov/ct2/show/NCT04944030


Rehabilitation Treatment and Early Recovery After "Wedge Resection" for Pulmonary Metastasis Secondary to Bone Cancer: an Observational Study.

The prevalence of primary bone tumors in Italy is about 0. 8-1 case per 100,000 people, so an estimated 500 new cases of primary malignant bone tumors are reported each year, more commonly in children and young adults. Metastasis is present in 30% of the population with bone cancer, and it is the most common site of metastasis. Pulmonary wedge resection surgery does not follow the anatomical limits of the lung, but it can be customised according to the geographic area to be eliminated, thus distinguishing itself from lobectomies and other thoracotomy surgical procedures. In the diagnosis of pain and recovery of respiratory volumes, rehabilitation therapy is part of a multidisciplinary strategy for this population of patients in the prevention of post-surgical respiratory difficulties and shoulder girdle dysfunctions.

Source link: https://clinicaltrials.gov/ct2/show/NCT05310539


In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas

Sarcoma that has spread to the lungs is most often treated by surgery. Even with surgery, the majority of patients will not be cured and will die from their disease, mainly because of small cancer cells that are present in the lungs at the time of surgery, but cannot be detected or detected. Any microscopic cancer cells that are present in the lungs at the time of surgery may be able to be removed from the body's major organs due to chemotherapy's side effects. One lung will be treated with IVLP as a control lung, and the other lung will be untreated with the IVLP as a control lung. IVLP will be initiated following surgical isolation of the lung by proximal control of pulmonary artery and veins. The lung metastases will be removed in the normal manner after 3 hours of IVLP.

Source link: https://clinicaltrials.gov/ct2/show/NCT02811523

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions